• Je něco špatně v tomto záznamu ?

Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice

E. Češková, M. Šedová, R. Kellnerová, O. Starobová,

. 2018 ; 102 (3-4) : 206-212. [pub] 20180810

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19000470

OBJECTIVE: The aim of the study was to evaluate the efficacy, tolerability, and safety of once-a day trazodone tablets (Trittico Prolong® 300 mg) in patients with moderate to severe depression in routine clinical practice. METHODS: Men and women ≥18 years old with Montgomery-Åsberg Depression Rating Scale (MADRS) scores > 21 and Clinical Global Impression - Severity (CGI/S) ≥4 were included in this post-authorization, non-interventional, observational prospective safety study, conducted in 8 psychiatric centers in the Czech -Republic. The acute treatment phase lasted 5 weeks: 1 week of titration and 4 weeks of full-dose treatment. Patients had follow-up visits 9 and 21 weeks after commencing -treatment. RESULTS: Overall, 85 patients were enrolled in the study, of which 80 completed the acute treatment of 5 weeks. There were significant decreases in the overall MADRS score from the baseline mean value of 27.4-21.2 at week 1 (p < 0.001), and a further decrease to 7.9 at week 5 (p < 0.001). The severity of depression according to CGI/S gradually declined. Most patients reported improvement after 6 days of trazodone treatment. The most frequent adverse drug reactions (ADRs) reported were somnolence and fatigue. CONCLUSIONS: Trazodone, in the new extended-release formulation, had very good effects in clinical practice, both in previously untreated depressive episodes and in episodes not responsive to previous antidepressive therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000470
003      
CZ-PrNML
005      
20190115105304.0
007      
ta
008      
190107s2018 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000492079 $2 doi
035    __
$a (PubMed)30099450
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Češková, Eva $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic. Department of Psychiatry, Faculty Hospital Brno, Brno, Czech Republic. Department of Psychiatry, University Hospital Ostrava, Ostrava, Czech Republic. Department of Neurology and Psychiatry, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
245    10
$a Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice / $c E. Češková, M. Šedová, R. Kellnerová, O. Starobová,
520    9_
$a OBJECTIVE: The aim of the study was to evaluate the efficacy, tolerability, and safety of once-a day trazodone tablets (Trittico Prolong® 300 mg) in patients with moderate to severe depression in routine clinical practice. METHODS: Men and women ≥18 years old with Montgomery-Åsberg Depression Rating Scale (MADRS) scores > 21 and Clinical Global Impression - Severity (CGI/S) ≥4 were included in this post-authorization, non-interventional, observational prospective safety study, conducted in 8 psychiatric centers in the Czech -Republic. The acute treatment phase lasted 5 weeks: 1 week of titration and 4 weeks of full-dose treatment. Patients had follow-up visits 9 and 21 weeks after commencing -treatment. RESULTS: Overall, 85 patients were enrolled in the study, of which 80 completed the acute treatment of 5 weeks. There were significant decreases in the overall MADRS score from the baseline mean value of 27.4-21.2 at week 1 (p < 0.001), and a further decrease to 7.9 at week 5 (p < 0.001). The severity of depression according to CGI/S gradually declined. Most patients reported improvement after 6 days of trazodone treatment. The most frequent adverse drug reactions (ADRs) reported were somnolence and fatigue. CONCLUSIONS: Trazodone, in the new extended-release formulation, had very good effects in clinical practice, both in previously untreated depressive episodes and in episodes not responsive to previous antidepressive therapy.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antidepresiva druhé generace $x aplikace a dávkování $x škodlivé účinky $7 D018687
650    _2
$a deprese $x farmakoterapie $7 D003863
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a nežádoucí účinky léčiv $7 D064420
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a psychiatrické posuzovací škály $7 D011569
650    _2
$a selektivní inhibitory zpětného vychytávání serotoninu $x aplikace a dávkování $x škodlivé účinky $7 D017367
650    _2
$a trazodon $x aplikace a dávkování $x škodlivé účinky $7 D014196
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Šedová, Michaela $u Institute of Biostatistics and Analyses Brno, Brno, Czech Republic.
700    1_
$a Kellnerová, Renata $u Department of Medical Angelini Pharma, Brno, Czech Republic.
700    1_
$a Starobová, Olga $u Department of Psychology, Faculty of Arts, Masaryk University, Brno, Czech Republic.
773    0_
$w MED00003791 $t Pharmacology $x 1423-0313 $g Roč. 102, č. 3-4 (2018), s. 206-212
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30099450 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190115105514 $b ABA008
999    __
$a ok $b bmc $g 1364546 $s 1038593
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 102 $c 3-4 $d 206-212 $e 20180810 $i 1423-0313 $m Pharmacology $n Pharmacology $x MED00003791
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Možnosti archivace